Presentations from GSIPA2M 2018

Here you can browse presentations from our inaugural Global Summit on Intellectual Property and Access to Medicines (GSIPA2M), which took place 15-17 January 2018,  Marrakech, Morocco.

Marrakech was home to the signing of the TRIPS Agreement in 1995, an agreement that has been exploited by pharmaceutical companies to drive medicines where there is the greatest profit rather than the greatest need. 23 years later, our summit gathered people with the knowledge and skills to redress the balance.

View the speakers’ presentations by day and session below.
To view full-screen, click the arrows which can be found at the bottom right of each PowerPoint presentation.

  • Day 1: Opening session

    Our opening session speakers were: Alia Amimi and Khadija El Gabsi, ITPC MENA, Morocco; Veriano Terto, ABIA, Brazil; Jorge Mermudez, UN High Level Panel on Access to Medicines; Solange Baptiste, ITPC Global, and representatives from the Government of Morocco.

    View day 1 presentations from the opening session.

  • Day 1: Plenary 1 – Two decades of TRIPS

    Our first plenary session: Return to Marrakech: Two decades of TRIPS and access to medicines. The focus of the presentations included looking at the difference between the cost and prices of medicines; the use TRIPS flexibilities, asking whether they are enough; describing examples where they have been used; and looking at patent law reform as an option.

    View presentations from day 1 – two decades of TRIPS.

  • Day 1: Plenary 2 – The role of civil society

    This session looked at the role of civil society in the implementation of TRIPS flexibilities . This included examples of challenging the tactics of ‘Big Pharma’, such as patent oppositions, compulsory licenses, patent law reform, and monitoring the effect of intellectual property on public health.

    View day 2 presentations on the role of civil society.

  • Day 1: Parallel session 1 – Preventing bad patents

    This session looked at the role of patent examination in preventing unmerited patents. Views and experiences were shared by civil society organizations, lawyers, and others, including perspectives from the patent offices themselves.

    View day 1 presentations on preventing bad patents, the role of patent examination.

  • Day 1: Parallel session 2 – Making CLs routine

    Countries have a right under the TRIPS Agreement to issue compulsory licenses (CLs) in the interest of public health. However, pharmaceutical companies hit back hard because it reduces their exorbitant profits, even in cases when a patent is unmerited to begin with. Brook Baker (pictured) from Health GAP, moderated the session.

    View day 1 presentations on making compulsory licenses (CLs) routine.

  • Day 2: Plenary 3 – Leaving TRIPS behind

    Day 2 started by looking at Leaving TRIPS behind: Understanding and resisting TRIPS-plus measures. This included examining the impact of some trade agreement deals on access to medicines.

    View day 2 presentations from plenary 3, Leaving TRIPS behind.


  • Day 2: Roundtable 1 – TRIPS-minus

    This first roundtable discussed how ‘least developed countries’ (LDCs) can make effective use of the transition periods, including what civil society groups need to do to support their governments in maintaining their rights during this period.

    View the presentations delivered in this roundtable discussion.

  • Day 2: Roundtable 2 – Local production and technology transfer

    The second roundtable of day 2 looked at local production and technology transfer, including why local production is so important, and government policies that can be employed to support this.

    View the presentations on local production.

  • Day 2: Roundtable 3 – Pro-health patent law reform

    Speakers addressed the possibilities and challenges in achieving law reform, which is essential to focus on as the continued over-protection of pharmaceutical companies is killing people.

    View the presentations on pro-heath law reform.

  • Day 2: Roundtable 4 – Challenging unmerited patents

    Looking at the successes and challenges in preventing or appealing unmerited patents – both from civil society and patent offices’ persepctives.

    View the presentations on challenging unmerited patents here.

  • Day 2: Plenary panel – sustaining civil society work on IP

    The final session of day 2 looked at how to sustain and support civil society work on intellectual property (IP) and access to medicines, which included hearing from two of the key donors of the Make Medicines Affordable campaign – UNITAID and aidsfonds.

    View the presentations on sustaining civil society work on IP.

  • Day 3: Closing plenary – A radical agenda?

    We asked if what’s been described over the Summit with regards to patents and access to medicines is a radical agenda. We believe the agenda needs to be radical – and that these changes are also achievable.

    View the closing plenary presentations.

  • Day 3: Rapporteur notes

    Our closing session included some passionate speeches, referring back on what’s been said as well looking forward. During the session, the 2018 Leadership Award on Intellectual Property and Access to Medicines was granted to Malaysia’s Ministry of Health.

    Read the rapporteur notes here.